Digilab BioVisioN GmbH closes cooperation agreement with Boehringer Ingelheim
Digilab BioVisioN GmbH announced closing of a cooperation contract with Boehringer Ingelheim Pharma GmbH & Co. KG. This is the first collaboration contract of the company that takes over commercial activities from BioVisioN AG within a reorganization process.
Within the project Digilab BioVisioN will analyze the quantitative peptide content of biological samples for the German pharmaceutical company. Using the patent-protected Peptidomics®-Technologies of Digilab BioVisioN, differences in peptide patterns are sought in order to identify new biomarkers. Further details of the project were not released.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.